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Abstract
Background:  Overweight is associated with an increased cardiovascular risk which is only
partially explained by conventional risk factors. The objective of this study was to evaluate
lipoprotein(a) [Lp(a)] plasma levels and apolipoprotein(a) [apo(a)] phenotypes in relation to
coronary heart disease (CHD) in overweight subjects.
Methods: A total of 275 overweight (BMI ≥ 27 kg/m2) subjects, of which 155 had experienced a
CHD event, 337 normal weight subjects with prior CHD and 103 CHD-free normal weight
subjects were enrolled in the study. Lp(a) levels were determined by an ELISA technique and apo(a)
isoforms were detected by a high-resolution immunoblotting method.
Results: Lp(a) levels were similar in the three study groups. Overweight subjects with CHD had
Lp(a) concentrations significantly higher than those without [median (interquartile range): 20 (5–
50.3) versus 12.6 (2.6–38.6) mg/dl, P < 0.05]. Furthermore, overweight subjects with CHD showed
a higher prevalence of low molecular weight apo(a) isoforms than those without (55.5% versus
40.8%, P < 0.05) and with respect to the control group (55.5% versus 39.8%, P < 0.05). Stepwise
regression analysis showed that apo(a) phenotypes, but not Lp(a) levels, entered the model as
significant independent predictors of CHD in overweight subjects.
Conclusions: Our data indicate that small-sized apo(a) isoforms are associated with CHD in
overweight subjects. The characterization of apo(a) phenotypes might serve as a reliable biomarker
to better assess the overall CHD risk of each subject with elevated BMI, leading to more intensive
treatment of modifiable cardiovascular risk factors.
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Background
Several studies revealed a strong relationship between ele-
vated body mass index (BMI) and coronary heart disease
(CHD) [1-3]. In fact, overweight has been recognized as a
modifiable cardiovascular risk factor [4]. The association
between body weight and cardiovascular events, however,
is influenced by several other cardiovascular risk factors,
including age, gender, hypertension, smoking, diabetes,
and hypercholesterolemia [2,5]. It implicates that in iden-
tifying overweight subjects with a particularly high CHD
risk, it is useful to analyse various cardiovascular risk fac-
tors in order to better assess the overall CHD predisposi-
tion of each subject with increased BMI. In addition to the
conventional cardiovascular risk factors, lipoprotein(a)
[Lp(a)] has been found to be a strong and independent
predictor of CHD [6-8]. Lp(a) consists of a low density
lipoprotein (LDL) particle linked with a single disulfide
bond to apolipoprotein(a) [apo(a)] [9].
Apo(a), the specific apolipoprotein of Lp(a), shows a
structural similarity with plasminogen [10] and is thought
to interfere with plasma fibrinolysis by inhibiting the gen-
eration of the thrombolytic enzyme plasmin [11]. It has
been therefore suggested that Lp(a) may display both
atherogenic and thrombogenic capacities [12]. Apo(a)
shows a high degree of genetic polymorphism, resulting
from differences in the number of kringle-IV (K-IV) type 2
repeats in the LPA gene located in 6q26-27 [13]. There are
several apo(a) isoforms of molecular weight varying from
280 to 820 kDa, encoded by an autosomal co-dominant
allele system [14]. A 'null' allele, which does not manifest
any type of isoform, has also been described [15].
Although the LPA gene, or sequences closely linked to it,
was believed to account for >90% of the variability in the
plasma Lp(a) level [16], it has been recently demonstrated
that the apo(a) length polymorphism explains only 38%
of the variability in Lp(a) concentration [17].
A number of investigations have demonstrated that small
apo(a) isoforms are associated to clinical CHD independ-
ent of the corresponding Lp(a) concentrations [18-20],
although these findings were not replicated by other
authors [21].
Furthermore, the evidence of an association between
apo(a) phenotypes and CHD in a large case-control study
of overweight (BMI ≥ 27 kg/m2) subjects is still lacking. To
evaluate the Lp(a)-related predisposition in the develop-
ment of CHD in overweight subjects, we determined
Lp(a) plasma levels and apo(a) phenotypes in a group of
275 overweight subjects and compared the overweight
subjects who had a prior CHD with those who did not.
Methods
Study population
A total of 275 overweight (BMI ≥ 27 kg/m2) Caucasian
Italian subjects (211 males and 64 females; mean age
61.36 ± 10.39 years; BMI 29.67 ± 2.56 kg/m2) were
recruited among the patients attending the Cardiology
Division, IRCCS San Matteo Hospital, Pavia. For each
enrolled subject, body weight was measured to the nearest
kg and height to the nearest centimeter. BMI was calcu-
lated as body weight divided by height2 (kg/m2). Accord-
ing to previous methodology [22-24], we used a BMI ≥ 27
kg/m2 as the criterion for inclusion in the overweight
group. Furthermore, this cut-off was chosen since it has
been previously adopted as the criterion to indicate over-
weight in a Western Europe population [25].
We then assembled an age- and gender-matched normal
weight control group, consisting of 103 subjects (74 males
and 29 females; mean age 61.95 ± 14.79 years; BMI 23.92
± 1.88 kg/m2). Controls were, mainly, individuals who
visited the outpatients' internal medicine department of
the same hospital and at the same period with the coro-
nary patients, for routine clinical or laboratory examina-
tions. Controls were subjects without any clinical
symptoms, signs or any suspicion of cardiovascular dis-
ease in their medical history, as determined by a physician
[26].
Among the overweight subjects, 107 (38.9%) subjects suf-
fered from diabetes mellitus, which was diagnosed
according to the ADA criteria [27], or the use of insulin or
oral hypoglycemic drugs. 173 (62.9%) overweight sub-
jects were hypertensive. Diagnosis of hypertension was
performed as either the blood pressure measured was
higher than 140/90 mmHg or by the need of antihyper-
tensive medications. Furthermore, 121 (44%) subjects
showed hypercholesterolemia, defined as a serum total
cholesterol major than 200 mg/dl, or the use of lipid low-
ering drugs [28]. Smoking was considered to be present if
the subject had smoked more than three cigarettes a day
for at least one year.
The overweight subjects were further divided into two
subgroups according to whether they had CHD or not.
The retrospective diagnosis of CHD was performed on the
basis of a documented history of myocardial infarction
(clinical history of retrosternal pain that lasted for at least
30 min without response to nitroglycerine, ST segment
elevation on a standard twelve-lead electrocardiogram
and an increase in serum creatine kinase to at least twice
the normal upper limit); coronary artery disease docu-
mented by angiography (stenosis > 75% in at least one
coronary artery); coronary artery bypass grafting or a pos-
itive history of anginous chest pain together with a posi-
tive exercise test. Among the overweight subjects, 155BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/12
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(56.3%) had CHD; for the other patients the possibility of
CHD was excluded on the grounds of their medical his-
tory and an exercise stress test, as described previously
[29].
In order to assess possible differences in the Lp(a)-associ-
ated risk between overweight and normal weight subjects,
337 normal weight subjects with CHD (251 males and 86
females; mean age 62.01 ± 11.18 years; BMI 23.85 ± 2.01
kg/m2), were recruited from the cardiology section.
The study protocol followed the guidelines of our local
ethics committee and all subjects gave full informed con-
sent to participate in the study.
Lp(a) quantification and apo(a) isoforms phenotyping
Venous blood was collected from subjects after an over-
night fast of about 12 hours. Quantification of Lp(a) and
phenotyping of apo(a) protein were done using plasma
obtained from blood collected in EDTA tubes, which were
centrifuged at 4°C, at low-speed, for 12 minutes. After
centrifugation, the plasma aliquots were frozen and
stored at -80°C.
Lp(a) plasma concentrations were determined by a sand-
wich-ELISA technique, using the commercially available
kit Macra-Lp(a) (SDI, Delaware, USA). The intra-assay
and inter-assay coefficients of variation of this method is
5 and 9%, without cross-reaction with plasminogen.
Apo(a) isoforms phenotyping was performed by an
immunoblotting method, as previously described in
detail [30], with slight modifications.
Briefly, 15 µL of EDTA-plasma samples were pretreated
with 30 µL of a reducing solution. The submarine electro-
phoretic run was performed on 1% sodium dodecyl sul-
fate-agarose gel and electrophoresis was carried out in
tank buffer for 14 h at 80 V and 0.04 A. Reduced samples
(20 µL) were applied in wells, at 3 cm from the cathode of
the gel. The separated proteins were transferred onto a
nitrocellulose membrane (Bio-Rad, Segrate, Italy) by a
capillary blotting technique and tested with a polyclonal
antihuman Lp(a) antiserum from rabbit (DAKO, Glos-
trup, Denmark). A peroxidase-conjugated goat antirabbit
immunoglobulin (DAKO, Glostrup, Denmark) was used
as the second antibody. Relative band mobility was deter-
mined as referred to apo(a) standard isoform mobility
included in each blot (values: 35, 27, 23, 19, and 14 K-IV
repeats; Immuno AG, Wien, Austria). Thus the estimated
number of K-IV repeats in each sample was calculated.
Statistical analysis
Normally distributed data are presented as means ± SD.
For Lp(a) levels, which showed a skewed distribution, we
used medians and interquartile ranges. Student's t test was
exploited for comparison in normally distributed data
between 2 groups and the Mann-Whitney U test was per-
formed for comparison of Lp(a) concentrations between
2 groups. Categorical variables were compared by means
of the chi-square test. The significance of clinical and bio-
chemical parameters as independent predictors of CHD in
overweight subjects was tested in stepwise regression anal-
ysis. Predictors or independent variables were: gender,
age, BMI, smoking, diabetes, hypertension, hypercholes-
terolemia, Lp(a) levels and apo(a) phenotypes. The crite-
rion for inclusion into the model was a P value less than
0.05, as determined with the F test. A probability value
below 0.05 was considered to indicate statistical signifi-
cance. All statistical analyses were performed using the
SPSS statistical package, version 11.0 for Windows (SPSS
Inc., Chicago, IL, USA).
Results
Baseline characteristics and Lp(a) levels of the study 
patients
Clinical characteristics of overweight subjects, normal
weight subjects with CHD and controls are summarized
in Table 1. Among the overweight subjects, the prevalence
of diabetes mellitus, hypertension and hypercholestero-
lemia was significantly higher than in controls. Among
the normal weight CHD subjects, the prevalence of smok-
ing and diabetes mellitus was significantly higher than in
controls, whereas no significant differences in the preva-
lence of hypertension and hypercholesterolemia were
found. Furthermore, no difference in median Lp(a) level
was found between the three study groups.
The features of overweight subjects with and without
CHD are shown in Table 2. The two groups show no sta-
tistically significant differences in age, gender, hyperten-
sion, smoking status and BMI. The CHD group included
significantly more subjects with diabetes mellitus and
hypercholesterolemia. Overweight subjects with CHD
had Lp(a) plasma significantly higher than those without
[median (interquartile range): 20 (5–50.3) versus 12.6
(2.6–38.6) mg/dl, P < 0.05].
Analysis of apo(a) polymorphism
Out of the 715 subjects recruited, we identified twenty-
three different apo(a) isoforms with molecular weight var-
ying from 400 and 835 kDa. The detection method
showed good sensitivity, specificity and reproducibility,
as described [30].
Because of the high degree of apo(a) polymorphism, we
divided apo(a) isoforms in two subgroups according to a
previously identified cut-off between 640 and 655 kDa.
This cut-off seems to discriminate well apo(a) isoforms
associated with higher atherothrombotic predispositionBMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/12
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[31]. According to previous methodology [19,32,33], we
decided to use only the smaller apo(a) isoform detected
for categorization.
Table 3 shows the apo(a) phenotype distribution in the
study groups. In the group of normal weight subjects with
CHD, low molecular weight apo(a) isoforms prevailed
(57%) and the difference in comparison with controls
was significant (P < 0.01).
In the subgroup of overweight patients with CHD low
molecular weight apo(a) isoforms were more prevalent
(55.5%), whereas among subjects without CHD apo(a)
isoforms of high molecular weight prevailed (59.2%). The
Table 1: Baseline characteristics and conventional atherothrombotic risk factors of the study groups
Overweight subjects Normal weight subjects with CHD Controls
No. of subjects 275 337 103
BMI, kg/m2 29.67 ± 2.56*** 23.85 ± 2.01 23.92 ± 1.88
Age, yr 61.36 ± 10.39 62.01 ± 11.18 61.95 ± 14.79
Male gender, n (%) 211 (76.7%) 251 (74.4%) 74 (71.8%)
Diabetes mellitus, n (%) 107 (38.9%)*** 168 (49.8%)*** 6 (5.8%)
Hypertension, n (%) 173 (62.9)** 184 (54.6%) 49 (47.5%)
Smokers, n (%) 32 (11.6%) 68 (20.2%)** 7 (6.8%)
Hypercholesterolemia, n (%) 121 (44%)** 115 (34.1%) 30 (29.1%)
Lp(a) (mg/dl) 16.2 (4–43) 19.6 (5.2–49) 14.9 (4.3–45.3)
BMI, body mass index; CHD, coronary heart disease; Lp(a), lipoprotein(a). Lp(a) levels are expressed as medians (interquartile range within 
brackets). **P < 0.01 ***P < 0.001, versus controls.
Table 2: Features and conventional atherothrombotic risk factors of overweight subjects with and without coronary heart disease 
(CHD)
CHD No CHD
n 155 120
BMI, kg/m2 29.39 ± 2.13 30.03 ± 3.00
Age, yr 61.70 ± 9.56 60.90 ± 11.40
Male gender, n (%) 120 (77.4%) 91 (75.8%)
Diabetes mellitus, n (%) 83 (53.4%) 24 (20%)***
Hypertension, n (%) 93 (60%) 85 (70.8%)
Smokers, n (%) 33 (21.3%) 20 (16.7%)
Hypercholesterolemia, n (%) 80 (51.6%) 41 (34.1%)**
Lp(a) (mg/dl) 20 (5–50.3) 12.6 (2.6–38.6)*
BMI, body mass index; Lp(a), lipoprotein(a). Lp(a) levels are expressed as medians (interquartile ranges within brackets). *P < 0.05 **P < 0.01 ***P 
< 0.001, versus CHD
Table 3: Apo(a) phenotypes distribution in the study groups.
n Subjects with at least one apo(a) isoform of low 
molecular weight
Subjects with only apo(a) isoforms of high 
molecular weight
Overweight subjects with CHD 155 86 (55.5%)* 69 (44.5%)
Overweight subjects without CHD 120 49 (40.8%) 71 (59.2%)
Normal weight subjects with CHD 337 192 (57%)** 145 (43%)
Controls 103 41 (39.8%) 62 (60.2%)
*P < 0.05 **P < 0.01, versus controls.BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/12
Page 5 of 7
(page number not for citation purposes)
difference between the two groups of overweight subjects
was statistically significant (P < 0.05).
The frequencies of apo(a) isoforms for the overweight
subjects with CHD and the CHD normal weight subjects
were similar. Furthermore, there was no significant
difference in the distribution of apo(a) isoforms between
overweight subjects without CHD and controls.
Multivariate analysis
The common cardiovascular risk factors, Lp(a) concentra-
tions and apo(a) isoforms of low molecular weight were
tested as predictors of CHD in overweight and normal
weight subjects in a stepwise regression analysis (Table 4).
The presence of diabetes mellitus, small-sized apo(a) iso-
forms, hypercholesterolemia, and BMI were found to be
significant predictors of CHD in overweight subjects. In
normal weight subjects the presence of diabetes mellitus,
smoking, hypercholesterolemia, hypertension and at least
one small-sized apo(a) isoform were found, in the order
they entered into the model, to be independent predictors
of CHD.
Discussion
In this report we investigated both Lp(a) concentrations
and apo(a) isoforms in a sample of overweight Caucasian
Italian subjects. The few studies available in the literature
that examined Lp(a) levels in overweight/obese subjects
gave rise to conflicting results. Indeed, Wassef et al [34]
found that obese subjects had higher Lp(a) levels than did
the control subjects, whereas Donatelli et al [35] reported
similar Lp(a) concentrations in normal glucose tolerant
obese subjects compared with controls. Although the
reasons for these contrasting findings remain unclear, dif-
ferent experimental designs, different number and charac-
teristics of subjects recruited, ethnical differences, medical
treatments (aspirin, beta carotene, lipid-lowering drugs),
lack of standardization of methods for the determination
of Lp(a) levels and different ways in which plasma sam-
ples were handled might at least partially explain the
differences among the studies. In any case, it has been
shown by Akanji et al [36] a significant correlation
between BMI and blood Lp(a) levels. Therefore, it seems
to be worthy of investigation whether Lp(a) levels and
apo(a) isoforms are independent risk factors for CHD in
overweight subjects.
In our study we found that Lp(a) plasma levels do not
seem to show significant differences between the whole
group of overweight and normal weight controls. How-
ever, we showed that Lp(a) plasma levels were
significantly higher in CHD overweight subjects with
respect to the CHD-free. This finding may be interpreted
in that it is possible to discriminate through Lp(a) levels
among CHD and CHD-free overweight subjects. How-
ever, this result should be considered with caution, since
stepwise regression analysis did not confirm an independ-
ent association between Lp(a) levels and CHD in our sam-
ple of overweight subjects. Furthermore, a potential
methodological limitation of our study should be dis-
cussed. Indeed, Lp(a) quantification was performed with
a commercial method which may be potentially sensitive
to the size of apo(a) protein. Therefore, our results on
Lp(a) plasma levels should be at least in part confounded
by the influence of variation in apo(a) isoform size [37].
After these considerations, we decided to extend our anal-
ysis to the distribution of apo(a) isoforms in our sample
of overweight subjects. To date, no data concerning the
analysis of apo(a) phenotypes in relation to CHD in over-
weight subjects have been published. The analysis of
apo(a) size polymorphism in the subgroups of over-
weight subjects with or without CHD has indicated that
overweight subjects with CHD have a higher prevalence of
low molecular weight apo(a) isoforms, whereas over-
weight subjects without CHD showed a higher prevalence
of high molecular weight apo(a) phenotypes. The regres-
sion analysis confirmed that, among the cardiovascular
risk factors considered, the presence of at least one low
molecular weight apo(a) isoform is a reliable discrimi-
nant between overweight subjects with CHD and those
without.
Therefore, the main finding of this study is that low
molecular weight apo(a) isoforms seem to be associated
with CHD not only in normal weight but also in over-
weight subjects. In overweight subjects, the CHD predis-
position related to the genetically determined apo(a)
Table 4: Results of stepwise regression analysis with the presence 
of coronary heart disease (CHD) as the dependent variable in 
overweight and normal weight subjects.
Overweight subjects
Predictor step t P value
Diabetes mellitus 1 5.892 <0.0001
Apo(a) isoforms of low molecular weight 2 2.665 0.008
Hypercholesterolemia 3 2.466 0.014
BMI 4 2.120 0.035
Normal weight subjects
Diabetes mellitus 1 8.521 <0.0001
Smoking 2 4.135 <0.0001
Hypercholesterolemia 3 3.296 0.001
Hypertension 4 3.097 0.002
Apo(a) isoforms of low molecular weight 5 2.500 0.013BMC Cardiovascular Disorders 2003, 3 http://www.biomedcentral.com/1471-2261/3/12
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isoforms should be added to the CHD risk due to
increased BMI and other risk factors associated with over-
weight. Furthermore, it seems to be reasonable to hypoth-
esize that overweight subjects with at least one apo(a)
isoform could be prone to an earlier development of
atherothrombotic complications. Such a risk could be
related to both the proatherogenic and thrombogenic
effect of small-sized apo(a) isoforms, since it has been
recently demonstrated that low molecular weight apo(a)
isoforms display a high antifibrinolytic activity and could
be involved in fibrinolysis impairment [38].
Interestingly, it should be noted that the higher preva-
lence of low molecular weight apo(a) isoforms in CHD
overweight subjects was associated with higher Lp(a)
plasma levels, whereas this was not the case of normal
weight CHD subjects. In any case, it has been recently
shown that the contribution of the apo(a) isoform size to
the control of plasma Lp(a) level is considerably lower
than previously calculated, because the variability in
plasma Lp(a) concentration is not uniform across the
apo(a) size spectrum [17].
Conclusions
Our results indicate that apo(a) isoforms are reliable
markers for CHD predisposition in subjects with elevated
BMI, and should be used together with other risk factors
to assess the overall risk status for CHD in overweight
subjects.
Finally, it should be emphasized the importance of apo(a)
phenotyping among overweight patients, since the identi-
fication of at least one apo(a) isoform of low molecular
weight may be useful in guiding the physician toward a
better control of modifiable cardiovascular risk factors
among overweight subjects, and could therefore reduce
the negative impact of coronary heart disease in subjects
with elevated BMI.
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